Zila Requests NASDAQ Investigation

Business Wire, Oct 7, 2008

PHOENIX -- Zila, Inc. (Nasdaq:ZILAD) today announced that, as a result of suspicious end-of-day trading in the Company's stock during the past several weeks, the Company has made an urgent request that NASDAQ undertake an investigation to determine the reasons for this activity.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, Arizona, is a diagnostic company dedicated to the prevention, detection and treatment of oral cancer and periodontal disease. Zila manufactures and markets ViziLite([R]) Plus with TBlue([R]) ("ViziLite([R]) Plus"), the company's flagship product for the early detection of oral abnormalities that could lead to cancer. ViziLite([R]) Plus is an adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer. In addition, Zila designs, manufactures and markets a suite of proprietary products sold exclusively and directly to dental professionals for periodontal disease, including the Rotadent([R]) Professional Powered Brush, the Pro-Select Platinum([R]) ultrasonic scaler and a portfolio of oral pharmaceutical products for both in-office and home-care use. All of Zila's products are marketed and sold in the United States and Canada primarily through the company's direct field sales force and telemarketing organization. The company's products are marketed and sold in other international markets through the direct sales forces of third party distributors. Zila's marketing programs reach most U.S. dental offices and include continuing education seminars for dentists and their staffs. Zila is certified by the American Dental Association and the Academy of General Dentistry to provide continuing education seminars.

For more information about the Company and its products, please visit www.zila.com.